Annons

The EU Commission grants conditional approval for Idefirix[TM] (imlifidase) in highly sensitized kidney transplant patients in the European Union

The conditional approval by the European Commission serves as a landmark milestone for Hansa Biopharma, as Idefirix[TM] (imlifidase) will be the Company’s first approved drug and will transform Hansa Biopharma into a commercial stage biopharmaceutical company

Lund, Sweden August 26, 2020. Hansa Biopharma (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the European Commission has granted conditional approval for IdefirixTM in highly sensitized kidney transplants patients.

The formal approval by the European Commission was received two months after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending conditional approval of Idefirix for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.

“We are very excited about today’s decision from the European Commision to approve Idefirix in highly sensitized kidney transplant patients. This is the first approved drug for Hansa Biopharma and will bring hope to the thousands of highly sensitized patients across Europe waiting for a life-saving kidney transplant” says Søren Tulstrup, President & CEO of Hansa Biopharma.

“Today’s approval further serves as a validation of the potential of Hansa Biopharma’s proprietary drug development engine and will transform the company into a commercial stage biopharmaceutical company that brings lifesaving and life altering therapies to patients with rare diseases who need them and generate value to society at large.” 

Idefirix has been reviewed as part of the European Medicines Agency’s (EMA) PRIority MEdicines (PRIME) programs, which support medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options.

The first treatments with Idefirix is expected to be available to patients in select European countries during the fourth quarter 2020, as communicated earlier. 

A post-approval study will be initiated in parallel with the launch following the market authorization.

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

Följande bilagor finns för nedladdning:
Release

Se fullständigt pressmeddelande och andra nyheter från detta bolag på Cision News.
Vill du också synas med dina nyheter på Di.se?
Läs mer om publicering på Di.se


Vi använder cookies för att förbättra funktionaliteten på våra sajter, för att kunna rikta relevant innehåll och annonser till dig och för att vi ska kunna säkerställa att tjänsterna fungerar som de ska. Läs mer i vår cookiepolicy.
Läs mer

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till di.se med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr

Prenumerera

Redan prenumerant?